The FDA approves Incyte's Jakafi (ruxolitinib) for the treatment of steroid-refractory acute graft-versus-host disease (GvHD) in patients at least 12 years old. The kinase inhibitor was previously approved in the U.S. to treat myelofibrosis and polycythemia vera.
Copyright © 2024 | J. LAMARCK S.P.A. Powered by Moving